苯达莫司汀联合利妥昔单抗治疗惰性B细胞非霍奇金淋巴瘤的效果  

Efficacy of bendamustine combined with rituximab on inert B-cell non-Hodgkin’s lymphoma

作　　者：黄文娟[1] 王莉[2] 黄瑛 周志刚[1] 李皎[1] 张云平[1] HUANG Wenjuan;WANG Li;HUANG Ying;ZHOU Zhigang;LI Jiao;ZHANG Yunping(Department of Hematology,Yixing People’s Hospital,Jiangsu,Yixing 214221,China;Department of Hematology,Jiangsu Province Hospital,Jiangsu,Nanjing 210029,China)

机构地区：[1]江苏省宜兴市人民医院血液科,江苏宜兴214221 [2]江苏省人民医院血液科,江苏南京210029

出　　处：《中国医药科学》2023年第11期116-119,共4页China Medicine And Pharmacy

摘　　要：目的分析苯达莫司汀联合利妥昔单抗治疗惰性B细胞非霍奇金淋巴瘤(B-iNHL)的效果。方法回顾性分析2020年1月至2021年3月在宜兴市人民医院和江苏省人民医院治疗的45例B-iNHL患者。根据治疗方法不同分为对照组(n=20)和观察组(n=25),对照组给予利妥昔单抗+环磷酰胺+表柔比星+长春新碱+泼尼松(R-CHOP)方案治疗,观察组给予苯达莫司汀+利妥昔单抗(BR)方案治疗。比较两组临床疗效、生存率、不良反应和生命质量核心问卷(QLQ-C30)评分。结果两组完全缓解率、客观缓解率、1年无进展生存率和1年总生存率比较,差异无统计学意义(P>0.05)。观察组白细胞减少、中性粒细胞减少、恶心呕吐、脱发、发热的发生率低于对照组(P<0.05)。治疗后,两组QLQ-C30评分均降低(P<0.05),但观察组高于对照组(P<0.05)。结论BR方案治疗B-iNHL的效果与R-CHOP方案相当,但不良反应小,对生存质量影响小。Objective To analyze the efficacy of bendamustine combined with rituximab in the treatment of inert B-cell non-Hodgkin’s lymphoma(B-iNHL).Methods A total of 45 patients with B-iNHL admitted to and treated in Yixing People’s Hospital and Jiangsu Province Hospital from January 2020 to March 2021 were analyzed retrospectively.According to different treatment methods,the patients were divided into the control group(n=20)and the observation group(n=25).The control group was treated with the regimen of rituximab+cyclophosphamide+epirubicin+vincristine+prednisone(R-CHOP),while the observation group was treated with bendamustine+rituximab(BR).The clinical efficacy,survival rate,adverse reactions and core quality of life questionnaire(QLQ-C30)scores were compared between the two groups.Results There were no statistically significant differences in complete remission rate,objective remission rate,1-year progression-free survival rate and 1-year overall survival rate between the two groups(P>0.05).The incidences of leukopenia,neutropenia,nausea and vomiting,alopecia and fever in the observation group were lower than those in the control group(P<0.05).After treatment,the QLQ-C30 scores of both groups decreased(P<0.05),but the score of the observation group was higher than that of the control group(P<0.05).Conclusion The efficacy of BR regimen in the treatment of B-iNHL is similar to that of R-CHOP regimen,but the adverse reaction of the former is less,which has little impact on the quality of life.

关 键 词：苯达莫司汀 利妥昔单抗 惰性B细胞非霍奇金淋巴瘤 临床效果 安全性 

分 类 号：R733.1[医药卫生—肿瘤]